Innova Therapeutics has completed the acquisition of Enci Therapeutics, including its lead cancer therapeutic program IVT-8086, a humanized monoclonal antibody targeting SFRP2 for treating solid and hematological cancers.
Related articles
Press ReleaseMay 8, 2026
West Enclave Merger Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing May 13, 2026
May 8, 2026
Press ReleaseMay 8, 2026
Shreya Acquisition Group Announces Closing of $110 Million Initial Public Offering (Including Partial Exercise of Over-Allotment Option)
May 8, 2026
Press ReleaseMay 8, 2026
Con Edison Announces $2 Billion At-The-Market (ATM) Equity Offering Program
May 8, 2026
← Back to all articles
Generated by Yeal